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Background: The practice of clinical medicine rests on a foundation of ethical principles as well as scientific
knowledge. Clinicians must artfully balance the principle of beneficence, doing what is best for patients, with
autonomy, allowing patients to make their own well-informed health care decisions. The clinical communication
process is complicated by varying degrees of confidence in scientific evidence regarding patient-oriented benefits,
and by the fact that most medical options are associated with possible harms as well as potential benefits.
Discussion: Evidence-based clinical guidelines often neglect patient-oriented issues involved with the thoughtful
practice of shared decision-making, where individual values, goals, and preferences should be prioritized. Guidelines
on the use of statin medications for preventing cardiovascular events are a case in point. Current guidelines
endorse the use of statins for people whose 10-year risk of cardiovascular events is as low as 7.5 %. Previous
guidelines set the 10-year risk benchmark at 20 %. Meta-analysis of randomized trials suggests that statins can
reduce cardiovascular event rates by about 25 %, bringing 10-year risk from 7.5 to 5.6 %, for example, or from 20 to
15 %. Whether or not these benefits should justify the use of statins for individual patients depends on how those
advantages are valued in comparison with disadvantages, such as side effect risks, and with inconveniences
associated with taking a pill each day and visiting clinicians and laboratories regularly.
Conclusions: Whether or not the overall benefit-harm balance justifies the use of a medication for an individual
patient cannot be determined by a guidelines committee, a health care system, or even the attending physician.
Instead, it is the individual patient who has a fundamental right to decide whether or not taking a drug is
worthwhile. Researchers and professional organizations should endeavor to develop shared decision-making tools
that provide up-to-date best evidence in easily understandable formats, so as to assist clinicians in helping their
patients to make the decisions that are right for them.
Keywords: Attitude to health, Cholesterol, Clinical significance, Cost-benefit analysis, Decision making, Evidence-based
medicine, Guidelines, Lipids, Minimal important difference, Outcomes, Patient preference, Preventive cardiology,
Primary care, Quality of life, Shared decision-making, StatinsBackground
The practice of medicine rests on foundations of know-
ledge accumulated over centuries, from simple observa-
tion to large and rigorous randomized controlled trials
(RCTs). Following the principles of evidence-based
medicine, systematic reviews of RCTs allow for authori-
tative interpretation of best available evidence. And yet,
even with well-proven medical interventions, there are
potential harms as well as benefits, which may be valued* Correspondence: bruce.barrett@fammed.wisc.edu
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(http://creativecommons.org/publicdomain/zequite differently by individual patients. This, combined
with varying levels of understanding among clinicians
and patients, yields substantive complexity and uncer-
tainty at the individual decision-making level. This paper
uses the example of statins for preventing cardiovascular
events (heart attacks and strokes, primarily), to discuss
the principles and practice of evidence-informed shared
decision-making, emphasizing the importance of individ-
ual values, and the effective communication of
probabilities.
Cardiovascular (CV) disease, causing heart attack,
stroke and other CV events, is the leading cause of death
and disability in the developed world [1, 2]. Of theis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Main point summary
Clinical decision-making should be guided by patient values as well as
best available evidence
Virtually all medical interventions have potential harms as well as
potential benefits
Benefits and harms vary in terms of frequency, magnitude, impact, and
importance to patients
Recently released guidelines endorse the use of statins to prevent
cardiovascular (CV) events when the estimated 10 year CV event risk is
as low as 7.5 %, a major change from previous guidelines, which
endorsed preventive treatment when 10-year risk was 20 % or higher
Best evidence suggests that taking a statin pill every day for 10 years
would reduce a 7.5 % risk by about 1.9 to 5.6 %. Similarly, a 20 %
10-year event risk could be reduced to 15 %.
Potential harms of statins are very low, but include myopathy, diabetes,
and hepatotoxicity
Whether benefit harm trade-offs make a statin worthwhile is an
individual patient decision
Practicing clinicians and health care delivery systems should strive to
communicate best available evidence so that patients are able to make
informed decisions about their health
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(genetic predisposition) are fixed, but blood pressure,
cholesterol, blood sugar, tobacco use, stress, depression,
diet, and exercise are all considered targets in the effort
to reduce the impact of heart attack, stroke, and other
patient-oriented CV outcomes.
For people with the CV risks of dyslipidemia, hyper-
tension and diabetes, numerous pharmaceutical inter-
ventions are available. For people with moderate to
severe hypertension, several classes of drugs appear to
be effective in reducing stroke and heart attack risk [3,
4]. For mild hypertension, evidence of pharmaceutical
effectiveness is less clear [5, 6]. Drugs aimed at diabetes
can improve glycemic control, and may improve some
microvascular outcomes, but have marginal effects on
CV outcomes [7, 8]. While several types of cholesterol-
targeting drugs have been shown to modify the lipid
profile in favorable directions, only statins (HMG co-A
reductase inhibitors) have been shown to reduce CV
event rates [2, 9–11].
In the past several years, there has been a minor in-
crease in evidence available regarding statins for pre-
venting CV events, and a major change in the
translation of evidence into guidelines [12–14]. The re-
cent 2013 American Heart Association and American
College of Cardiology (AHA/ACC) guidelines endorse
statin treatment when 10 year CV event risk is as low as
7.5 %, [15] and the 2014 U.K. National Institute for
Health and Care Excellence (NICE) guidelines suggest
that clinicians “Offer atorvastatin 20 mg for the primary
prevention of CVD to people who have a 10 % or greater
10-year risk of developing CVD” [2]. Only a few years
earlier, guidelines from the same organizations sup-
ported statins only for people with 20 % or higher 10 year
CVD event risk [16, 17].
This article focusses on statins for preventing CV
events, but the principles of evidence-informed shared
decision-making apply widely. See Table 1. The aims of
this article are to:
1) Summarize current evidence regarding statins for
preventing CV events
2) Identify limitations of the most recent guidelines
3) Outline an evidence-informed approach towards
shared decision making
4) Use two case examples to illustrate this approach
5) Suggest a few potentially fruitful future directions
for the development and use of clinical guidelines
and decision aids
Discussion
In order to frame our discussion of evidence regarding
benefits, harms, uncertainty, and the complex task of
shared decision-making, we present two hypotheticalpatients for your consideration. Please imagine that you
practice general outpatient medicine and are familiar
with the current guidelines.
Your first patient, Joe Smith, is a 45 year old non-
smoking man with total cholesterol of 220 mg/dL and
HDL of 30 mg/dL. He is taking chlorthalidone for hyper-
tension, and his last blood pressure was 142/82 mmHg.
According to the risk calculator available at http://
cvdrisk.nhlbi.nih.gov [18] he has a 7 % chance of having
a heart attack over the next 10 years, and hence may not
be eligible for a statin according to the guideleines.
However, he tells you that his heavy smoking father had
a fatal heart attack at age 46, and that he wants to do
everything he can to avoid a similar fate.
Your second patient, Mary Jones, also has a total chol-
esterol of 220 mg/dL and an HDL of 30 mg/dL. She is a
60 year old pack-a-day smoker with an untreated blood
pressure of 154/88 mmHg. According to the same risk
calculator, she has a 14 % 10-year risk of having a heart
attack. As far as she knows, no one in her family has
had a heart attack or stroke. She is reluctant to take
medications, for reasons of cost and convenience, and
also because several friends have had unacceptable side
effects when taking blood pressure or cholesterol lower-
ing medications.
Benefits
Statins, also known as HMG co-A reductase inhibitors,
have been studied extensively, and are considered
proven effective medicines. More than two dozen large
randomized controlled trials (RCTs) have enrolled more
than 175,000 study participants [9–11, 19–21]. For per-
haps two decades, statins have been considered
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(secondary prevention). Over the past several years,
there has been increasing consensus that statins used for
primary prevention may reduce the rate of initial CV
events, and related mortality, at least for those of suffi-
ciently high risk [9, 22]. However, the impact of statins
on all-cause mortality for people with dyslipidemia or
other risk factors, but without previously known vascular
disease, has been met with more controversy [9, 23].
Part of the controversy comes from the fact that many
of the individual trials failed to demonstrate mortality or
CV event reductions, perhaps because of inadequate
statistical power. Pooling data through meta-analysis in-
creases power, but brings limitations, including those re-
lated to diversity of populations sampled, outcomes
assessed, statistical methods used, and specific medica-
tions and doses tested. It may be important to note that
several of the so-called primary prevention trials in-
cluded some people with known CV disease. Illustrating
this point, a 2010 meta-analysis of 11 primary preven-
tion trials (65,229 participants) included only those with
high risk but no known CV disease, and failed to find
statistically significant all-cause mortality reduction ben-
efits [11]. However, the 2012 Cholesterol Treatment Tri-
alists’ (CTT) meta-analysis of 22 trials (n = 134,537) [10]
and the 2013 Cochrane report (18 trials; n = 56,934) [9]
both found evidence of all-cause mortality benefit, but
did include trials that had subjects with pre-existing CV
disease.
Regardless of whether all-cause mortality benefits can
be proven for moderate risk patients, it has become in-
creasingly clear that statins can reduce CV events and
associated mortality, and that these benefits appear to
exist in moderate as well as high risk populations [9, 10,
21, 24]. The CTT and Cochrane reports strengthened
consensus regarding the important benefits of statins,
which led to the new NICE and AHA/ACC guidelines,Table 2 Chances of cardiovascular event with or without statin ove
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Based on 25 % relative risk reduction (Taylor, 2013)
ARR absolute risk reduction, NNT number needed to treatwhich, if implemented widely, would dramatically in-
crease the number of people taking statins [25].
Accepting that benefits have been well-proven, a lo-
gical next step is to look at magnitude, or degree of
benefit. The 2012 CTT study focused on vascular event
rates as a function of low density lipoprotein (LDL), and
reported a 21 % relative risk reduction (RRR) per
1.0 mmol of LDL reduced (the average LDL reduction
was 1.07 mmol/L) [10]. The 2013 Cochrane analysis re-
ported an average RRR of 25 % for combined fatal and
nonfatal CV events (95 % CI 0.19 to 0.30). Because ac-
tual risk varies as a function of baseline risk, this would
translate to an absolute risk reduction of 5 % for a pa-
tient with a 20 % 10-year CV event risk, and 1.9 % for
someone with a 7.5 % baseline risk. The Cochrane meta-
analysis also reported statistically significant reductions
in all-cause mortality, with relative risk reductions of ap-
proximately 14 %. Applying that to a high risk person
with a 10-year chance of death of 10 % from any cause,
taking a statin could reduce that risk to 8.6 %. For some-
one with more moderate risks, the chance of a CV event
could be lowered from 10 to 7.5 %, for example, and the
chance of death from any cause from a 3 to 2.6 %, over
10 years. Table 2 displays absolute risk reduction and
number needed to treat benefits across a spectrum of
baseline risks, using the 25 % CV event RRR suggested
by the Cochrane analysts. We include 5-year as well as
10-year timespans as we feel the shorter timeline may be
more interpretable for many patients.
Harms
Statins are known to cause muscular pain and inflamma-
tion among some users [26–29]. The CTT collaboration
estimates that the risk of serious myopathy attributable
to statins is approximately 1 in 1000 users over a 10 year
period [10]. Other studies put the risk much higher. For
instance, a retrospective cohort study of 58,977 peopler 5-year and 10-year spans
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etal problems for those taking statins, corresponding to
a number needed to harm (NNH) of 47 [30]. In another
study of 107,835 people who had been prescribed a sta-
tin, some 57,292 discontinued, at least temporarily [31].
More than half of the 18,778 reported statin-related
events were due to muscle pain or inflammation [31].
Data from the National Health and Nutrition Examin-
ation Survey (NHANES), with a large representative
sample, reported a 50 % higher prevalence of muscle
pain among statin users vs. non-users, corresponding to
an NNH of 19 [32]. One trial randomized n = 1,016
people to pravastatin, simvastatin or placebo, and re-
ported significant impacts on perceived energy and exer-
tional fatigue in the statin groups [33]. Another small
RCT among high-risk patients reported an almost
complete blunting of laboratory-assessed cardiovascular
fitness-enhancing effects of exercise, among those ran-
domized to simvastatin, compared to placebo [34].
Statins are associated with increased incidence of dia-
betes [29, 35, 36]. A meta-analysis of 13 trials (91,140
participants) reported a 9 % relative risk increase of inci-
dent diabetes for those treated with a statin vs placebo,
which translates to about 5 new cases of diabetes for
every 1000 people taking a statin [35]. In the JUPITER
trial, an overall 25 % increase rate of incident diabetes
was reported in those randomized to rozuvastatin versus
placebo, with substantially higher rates among women,
suggesting about 28 new cases of diabetes per 1000
women per 5 years [37]. Additional diabetes risk data
come from the Women’s Health Initiative study, which
suggest a 48 % relative increase in new onset diabetes
among women taking statins [38]. Statin-associated dia-
betes risks appear to be dose-dependent, with higher
risks for those taking higher doses and high-intensity
statins [39].
In addition to myopathy and diabetes, a wide array of
statin-related side effects have been reported, but not
conclusively demonstrated. These include hepatotoxicity,
[29, 31, 40] cognitive impairment, [41] depression, [42]
irritability, [43] osteoarthritis, [30] sexual dysfunction,
[33] interstitial lung disease, [44] acute renal failure, [40]
and cataracts [40]. These potential adverse effects have
not been investigated rigorously, and different studies
have reported different results [45–47]. While the evi-
dence for statin-caused myopathy and diabetes is rea-
sonably convincing, estimates of degree-of-risk are
imprecise. For example, meta-analysis suggests that sta-
tins increase diabetes incidence by about 9 %, but the as-
sociated 95 % confidence intervals span a range from 2
to 17 %, [35] and, as noted above, the JUPITER trial test-
ing a high-intensity statin reported even higher diabetes
risk [37]. The European Atherosclerosis Society esti-
mates the overall risk of developing statin-related musclesymptoms to be anywhere from 7 to 29 % [48]. Most of
the other suspected adverse effects are even less well
understood, and are better described as associations ra-
ther than attributable consequences [29]. A major limi-
tation of the data regarding adverse effects derives from
trial design. While great efforts are spent assessing po-
tential benefits, the assessment of harms may be mini-
mized or neglected. As a result, benefits are often
understood with far greater confidence and precision
than are harms.
Uncertainty
There are several reasons why even the best RCTs and
meta-analyses provide limited information regarding in-
dividual benefit and harm probabilities. For example, the
validity of statistical inference depends on several as-
sumptions, including data distribution normality and
parameter independence, which are often not satisfied in
RCT data sets. Selection bias is also important. Trial
participants are rarely recruited using probability sam-
pling, hence are not representative of general at-risk
populations. This compromises both generalizability and
relevance to individual patients. Outcome assessment
and classification may be biased or limited, both by the
design of data-capture methods, and by those analyzing,
interpreting, and reporting outcomes. Blinding is often
an issue, both for participants and trialists. For example,
people randomized to placebo rather than statin will on
average have higher LDL levels, which might influence
decisions to stent or bypass coronary arteries. Revascu-
larization procedures are often considered “major vascu-
lar outcomes” and are included along with heart attacks
and stroke when assessing benefit rates, but may be in-
fluenced by unintentional unblinding. For example,
using the published CTT data but excluding revasculari-
zation procedures, Abramson found that, “for people at
low risk of cardiovascular disease (10 % risk over next
5 years), statins do not reduce the risk of death or ser-
ious illness” [49].
Guidelines versus shared decision making
Historical luminaries such as Hippocrates and Osler
exhorted physicians to place the patient’s interests above
their own, and to consider patient values for medical
decision-making. Nevertheless, only in recent decades
has the medical profession begun to shift from a pater-
nalistic “doctor knows best” stance towards one expli-
citly endorsing patient-centered, evidence-based, [50–
52] shared decision-making [53–55]. The growing
strength of patient-orientated shared decision-making in
the U.S. is exemplified by the focus on patient-centered
medical homes, [56, 57] the emphasis on patient-
oriented evidence that matters (POEMs), [58–60] and
the Patient-Centered Outcomes Research Institute
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oriented decision-making is highlighted in the Equity
and Excellence NHS white paper and in the National
Health Service Constitution [62, 63]. Following these di-
rectives, the NICE lipid guidelines state, “Treatment and
care should take into account individual needs and pref-
erences. Patients should have the opportunity to make
informed decisions about their care and treatment, in
partnership with their healthcare professionals” [2].
Despite official endorsement of considering patient
values, guideline committees often resort to a one-size-
fits-all approach towards clinical decisions. For example,
while the NICE guidelines leave open the possibility of
individualized decision-making by saying, “Offer atorva-
statin 20 mg for the primary prevention of CVD to
people who have a 10 % or greater 10-year risk of devel-
oping CVD,” the clinical decision for secondary preven-
tion seems to have been made without the patient being
consulted: “Start statin treatment in people with CVD
with atorvastatin 80 mg” [2] [Emphasis added]. The
AHA/ACC guidelines acknowledge but undermine a
patient-centered approach by stating, “The ultimate de-
cision about care of a particular patient must be made
by the healthcare provider and patient in light of the cir-
cumstances presented by that patient. As a result, situa-
tions might arise in which deviations from these
guidelines may be appropriate” [15]. This wording im-
plies that the recommended use of statins for people
with 10-year CVD risks of ≥7.5 % depicted in the
widely-reproduced decision tree should be considered as
standard, and that a choice to not use a statin would be
a deviation.
We are not the first to point out the tensions between
shared decision-making and clinical guidelines. Recent
editorials by Montori and colleagues discuss the risks of
practice guidelines that neglect patient preferences, [51]
and provide specific examples of how guidelines might
not apply to individual patients [12]. Research can pro-
vide estimates of benefit and harm probabilities among
populations, but even the best data cannot judge
whether the estimated benefit-harm balance makes
the intervention worthwhile for an individual patient.
Using evidence-based guidelines alone for clinical
decision-making violates the ethical principle of au-
tonomy by removing patients’ values, goals and vol-
ition from the equation.
The increasing use of patient decision aids (PDAs)
may be helpful in this regard, as there is good evidence
that the use of PDAs may improve patient understand-
ing, empower engagement and self-efficacy, and reduce
decisional conflict [64]. For example, the National Heart
Lung and Blood Institute [18] and the Mayo Clinic in
the U.S., [65] NICE in the U.K. [66] and the arriba group
in Germany [67] have developed PDAs using clearlanguage and simple figures to portray potential benefits
of statins for patients across various risk levels. The
NHLBI PDA is very simple and easy for patients to use,
but is limited in terms of risk factors included and CV
outcomes predicted. The German arriba system provides
a library of decision aids, perhaps helpful for busy clini-
cians wanting to use PDAs for a variety of clinical deci-
sions [68]. The Mayo PDA allows for individualized risk
estimation using any of three systems (AHA/ACC
ASCVD, Framingham, Reynolds), and potential benefits
in terms of two statin choices (standard vs. high inten-
sity). Predicted benefits are based on 25 % (standard) or
40 % (high intensity) relative risk reductions in CV event
rates. The NICE PDA predicts benefits based on 35 to
40 % relative risk reductions, and allows for individual-
ized calculation of increased risk of diabetes from statin
use. As very few of the trials in the CTT and Cochrane
analyses reported CV event rate reductions of 30 % or
greater, [10, 21] we feel that both the Mayo and the
NICE PDAs may be overly optimistic, and that the 25 %
RRR reported by the Cochrane group is more realistic
for most patients.
While patient decision aids are an important step for-
ward, the development and production of PDAs does
not ensure appropriate use in clinic. Even the most well-
designed PDAs are unlikely to be helpful if the clinician
and patient do not have sufficient time, communication
skills, or ability to understand benefit-harm probabilities
(numeracy) [69, 70]. Guidelines are often used to set
benchmarks for quality indicators, which are then used
to judge performance of organizations and individual cli-
nicians [71]. To us, it seems lamentable that clinicians
are sometimes judged by guideline-adherence rather
than ability to communicate evidence to assist patients
in making the choices that are right for them. The neg-
lect of shared decision-making in favor of seeking the
highest possible level of one-size-fits-all “quality” metrics
seems particularly misguided when one stops to think
about the lack of evidence regarding what those goals
should be. For example, to our best reading of the litera-
ture, there is no good evidence to help distinguish be-
tween the hypotheses that 80 % versus 20 % of the
population with, say, a 15 % 10-year risk of a having a
CV event, would want to take a statin for 10 years, if
they truly understood the evidence regarding benefit and
harm probabilities.
Guidelines provide benchmark cut-off points for
decision-making. Benefit harm probabilities, on the
other hand, naturally occur across continuums not easily
reduced to yes/no decisional alternatives. Someone with
an estimated 8 % 10-year risk may not have meaningfully
higher chances of a heart attack than someone with a
7 % risk. And yet, the 2013 ACC/AHA guidelines pro-
mote statins in one case but not in the other. The same
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guidelines. Additional concerns arise from the risk calcu-
lators themselves, which are based on a variety of as-
sumptions and data sets, and which yield a surprisingly
wide variety of event risk estimations [72, 73]. Should
treatment decisions change from one calculator to an-
other, or when different blood pressure readings or LDL
or HDL (high density lipoprotein) values from the same
individual are used?
We believe that patient-centered guidelines regarding
cholesterol treatment for CV event prevention should ac-
knowledge the risk continuum, and should strive to avoid
recommendations based on cut-off values. Future guide-
lines should strive to incorporate decision-aids and media
tools to help illustrate the risk continuum across treat-
ment choices. Expert panel recommendations should ex-
plicitly acknowledge that medical decisions should be
based on the preferences and values of well-informed pa-
tients, and not on some committee-approved interpret-
ation of randomized trial evidence. As such, guidelines
may be framed as suggestions to guide shared decision-
making, and not as directives for clinical care [51]. Phys-
ician performance and health care quality should not be
judged based on the proportion of patients whose deci-
sions fit within guideline recommendations.
Pathways forward
For several decades, medical culture has been undergo-
ing a gradual shift towards shared decision-making,
where the physician’s expert knowledge is a necessary
but insufficient ingredient when making medical deci-
sions. The emergence and evolution of evidence-based
medicine and shared decision-making are major leaps
forward, as patients, clinicians, and health care delivery
systems have an ever-improving set of tools and infor-
mation to draw upon. Increased recognition of the value
of the patient’s perspective and experiential knowledge is
leading to a broader conception of the process and pur-
pose of medical care [74, 75]. Nevertheless, central te-
nets of medicine, such as “first, do no harm”
(Hippocrates) and “treat the patient, not the disease”
(Osler) have changed little.
We suggest that the national organizations that de-
velop treatment guidelines should pay more attention to
potential harms, scientific uncertainties, and the clinical
context in which their proclamations may be applied.
Both national groups and local health care systems
should develop patient-friendly written, tabular and
graphical means of communicating evidence. Re-
searchers should work to fill in knowledge gaps, espe-
cially concerning harms, where the evidence from
pharma-funded clinical trials is woefully deficient.
One potentially fruitful research direction has to do
with assessment of benefit harm tradeoff judgments. Toimprove on the concept of “minimal important differ-
ence” [76] (which neglects harms), we defined “suffi-
ciently important difference” (SID) as “the smallest
amount of patient-valued benefit that an intervention
would require in order to justify associated costs, risks,
and other harms” [77–80]. At the individual level, SIDi is
the smallest amount of benefit that justifies the costs, in-
conveniences, risks and other harms associated with an
intervention. The SID, also known as “smallest worth-
while effect,” [81, 82] is an evidence-informed judgment
made by the person for whom the benefits or harms
might apply. At the population level, the distribution of
SID is largely unknown, but if assessed properly, could
go a long way towards guideline improvement. For ex-
ample, knowing the amount of benefit that would justify
an intervention for 10, 50 and 90 % of the population
(the SID10, SID50, SID90, respectively) could frame the
range over which treatments might be recommended.
For statin decision-making, the SIDi would be the mag-
nitude of CV event reduction that would justify the in-
creased risk of harms, costs and inconveniences
associated with taking the pills. Although that re-
search has yet to be done, we expect that SIDi values
would vary widely across the at-risk population.
People like Joe Smith with his estimated 7 % 10-year
heart attack risk might feel that statin benefits out-
weighed harms, which others like Mary Jones with
her 10-year 14 % risk might not.
Conclusions
There is strong evidence that statins can reduce the risk
of heart attacks and other cardiovascular events. The
degree-of-benefit increases across the risk spectrum, so
that people with higher risk derive greater benefit. For
example, best evidence suggests that someone with a
pre-existing 20 % 10-year risk of a CV event might re-
duce that risk by 5 to 15 %, while someone with a 7.5 %
estimated risk might reduce that risk by 1.9 to 5.6 %.
Probabilities of harms, such as inflammatory muscle
pain and increased incidence of diabetes are known less
precisely, but may be important to patients, and should
be taken into consideration. Other patient-oriented fac-
tors, such as the positive value of reassurance that one-
is-doing-all-that-one-can to prevent a heart attack, or
negatively-valued attributes, such as co-pays or other
monetary costs, or the hassle of having to take a pill
every day, or the need to regularly see doctors and have
blood drawn, may be important to patients, but have not
been assessed properly, and are not addressed by current
guidelines. Medicine’s guiding ethics, such as benefi-
cence and autonomy, have been recognized since Hip-
pocrates, and have in principle changed little since
Osler’s days. What has changed substantively is the qual-
ity and quantity of evidence available, and the gradual
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hope that this essay may beneficially contribute in this
direction.
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